ARTICLE | Company News
Advanced Life infectious news
January 10, 2011 8:00 AM UTC
Advanced Life will explore strategic alternatives, including an acquisition or partnership. The decision was based on the company's assessment of the financial resources required to conduct a registration program for its lead compound, Restanza cethromycin. Last year, Advanced Life received an SPA from FDA to conduct a Phase III trial of the oral ketolide antibiotic to treat community acquired bacterial pneumonia (CABP). ...